Literature DB >> 11606314

Adenosine-mediated hypotension in in vivo guinea-pig: receptors involved and role of NO.

P Nieri1, E Martinotti, V Calderone, M C Breschi.   

Abstract

1. Adenosine produced a biphasic lowering of the mean BP with a drastic bradycardic effect at the highest doses. The first phase hypotensive response was significantly reduced by the nitric oxide (NO) synthase inhibitor L-NAME. 2. The A(2a)/A(2b) agonist NECA produced hypotensive and bradycardic responses similar to those elicited by adenosine, which were not significantly modified by the A(2b) antagonist enprofylline. 3. The A(2a) agonist CGS 21680 did not significantly influence basal HR while induced a hypotensive response antagonized by the A(2a) selective antagonist ZM 241385, and reduced by both L-NAME and the guanylate cyclase inhibitor methylene blue. 4. The A(1) agonist R-PIA showed a dose-dependent decrease in BP with a drastic decrease in HR at the highest doses. The A(1) selective antagonist DPCPX significantly reduced the bradycardic activity and also the hypotensive responses obtained with the lowest doses while it increased those obtained with the highest ones. 5. The A(1)/A(3) agonist APNEA, in the presence of the xanthinic non-selective antagonist 8-pSPT, maintained a significant hypotensive, but not bradycardic, activity, not abolished by the histamine antagonist diphenhydramine. 6. The selective A(3) agonist IB-MECA revealed a weak hypotensive and bradycardic effect, but only at the highest doses. 7. In conclusion, in the systemic cardiovascular response to adenosine two major components may be relevant: an A(2a)- and NO-mediated hypotension, and a bradycardic effect with a consequent hypotension, via atypical A(1) receptors. Finally, an 8-pSPT-resistant hypotensive response not attributable to A(3) receptor-stimulation or to release of histamine by mastocytes or other immune cells was observed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606314      PMCID: PMC1572997          DOI: 10.1038/sj.bjp.0704301

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  Analysis of the atypical characteristics of adenosine receptors mediating negative inotropic and chronotropic responses of guinea-pig isolated atria and papillary muscles.

Authors:  N M Gardner; K J Broadley
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 2.  Receptors for purines and pyrimidines.

Authors:  V Ralevic; G Burnstock
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

Review 3.  Adenosine A2B receptors.

Authors:  I Feoktistov; I Biaggioni
Journal:  Pharmacol Rev       Date:  1997-12       Impact factor: 25.468

4.  Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia.

Authors:  C S Carr; R J Hill; H Masamune; S P Kennedy; D R Knight; W R Tracey; D M Yellon
Journal:  Cardiovasc Res       Date:  1997-10       Impact factor: 10.787

5.  A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia.

Authors:  K Stambaugh; K A Jacobson; J L Jiang; B T Liang
Journal:  Am J Physiol       Date:  1997-07

6.  Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor.

Authors:  J A Auchampach; X Jin; T C Wan; G H Caughey; J Linden
Journal:  Mol Pharmacol       Date:  1997-11       Impact factor: 4.436

7.  Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat.

Authors:  A Monopoli; C Casati; G Lozza; A Forlani; E Ongini
Journal:  J Pharmacol Exp Ther       Date:  1998-04       Impact factor: 4.030

8.  Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart.

Authors:  W R Tracey; W Magee; H Masamune; S P Kennedy; D R Knight; R A Buchholz; R J Hill
Journal:  Cardiovasc Res       Date:  1997-02       Impact factor: 10.787

9.  The role of A3 adenosine receptors in central regulation of arterial blood pressure.

Authors:  L Stella; V de Novellis; I Marabese; L Berrino; S Maione; A Filippelli; F Rossi
Journal:  Br J Pharmacol       Date:  1998-10       Impact factor: 8.739

10.  Cardiovascular effects of nitric oxide and adenosine in the nucleus tractus solitarii of rats.

Authors:  W C Lo; C R Jan; S N Wu; C J Tseng
Journal:  Hypertension       Date:  1998-12       Impact factor: 10.190

View more
  3 in total

1.  Glucose-induced intestinal vasodilation via adenosine A1 receptors requires nitric oxide but not K(+)(ATP) channels.

Authors:  Paul J Matheson; Na Li; Patrick D Harris; El Rasheid Zakaria; R Neal Garrison
Journal:  J Surg Res       Date:  2010-03-06       Impact factor: 2.192

2.  Optimization of Thermolytic Response to A1 Adenosine Receptor Agonists in Rats.

Authors:  Isaac R Bailey; Bernard Laughlin; Lucille A Moore; Lori K Bogren; Zeinab Barati; Kelly L Drew
Journal:  J Pharmacol Exp Ther       Date:  2017-06-26       Impact factor: 4.030

Review 3.  Purinoceptor: a novel target for hypertension.

Authors:  Xuan Li; Li-Juan Zhu; Jing Lv; Xin Cao
Journal:  Purinergic Signal       Date:  2022-02-18       Impact factor: 3.765

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.